vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and Limbach Holdings, Inc. (LMB). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $138.9M, roughly 2.6× Limbach Holdings, Inc.). LivaNova PLC runs the higher net margin — 8.6% vs 3.2%, a 5.4% gap on every dollar of revenue. On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs 4.3%). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs 6.6%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
Limbach Flugmotoren is a Chinese-owned company based in Germany that produces aircraft engines.
LIVN vs LMB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $138.9M |
| Net Profit | $30.9M | $4.4M |
| Gross Margin | 65.2% | 22.4% |
| Operating Margin | 11.8% | 0.8% |
| Net Margin | 8.6% | 3.2% |
| Revenue YoY | 12.1% | 4.3% |
| Net Profit YoY | -44.7% | — |
| EPS (diluted) | $0.57 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $138.9M | ||
| Q4 25 | $360.9M | $186.9M | ||
| Q3 25 | $357.8M | $184.6M | ||
| Q2 25 | $352.5M | $142.2M | ||
| Q1 25 | $316.9M | $133.1M | ||
| Q4 24 | $321.8M | $143.7M | ||
| Q3 24 | $318.1M | $133.9M | ||
| Q2 24 | $318.6M | $122.2M |
| Q1 26 | — | $4.4M | ||
| Q4 25 | $30.9M | $12.3M | ||
| Q3 25 | $26.8M | $8.8M | ||
| Q2 25 | $27.2M | $7.8M | ||
| Q1 25 | $-327.3M | $10.2M | ||
| Q4 24 | $55.9M | $9.8M | ||
| Q3 24 | $33.0M | $7.5M | ||
| Q2 24 | $16.3M | $6.0M |
| Q1 26 | — | 22.4% | ||
| Q4 25 | 65.2% | 25.7% | ||
| Q3 25 | 68.4% | 24.2% | ||
| Q2 25 | 67.8% | 28.0% | ||
| Q1 25 | 69.7% | 27.6% | ||
| Q4 24 | 68.2% | 30.3% | ||
| Q3 24 | 70.8% | 27.0% | ||
| Q2 24 | 68.7% | 27.4% |
| Q1 26 | — | 0.8% | ||
| Q4 25 | 11.8% | 9.4% | ||
| Q3 25 | 15.1% | 7.2% | ||
| Q2 25 | 15.4% | 7.5% | ||
| Q1 25 | 15.3% | 5.9% | ||
| Q4 24 | 11.5% | 9.1% | ||
| Q3 24 | 11.2% | 8.1% | ||
| Q2 24 | 12.6% | 6.7% |
| Q1 26 | — | 3.2% | ||
| Q4 25 | 8.6% | 6.6% | ||
| Q3 25 | 7.5% | 4.8% | ||
| Q2 25 | 7.7% | 5.5% | ||
| Q1 25 | -103.3% | 7.7% | ||
| Q4 24 | 17.4% | 6.9% | ||
| Q3 24 | 10.4% | 5.6% | ||
| Q2 24 | 5.1% | 4.9% |
| Q1 26 | — | $0.36 | ||
| Q4 25 | $0.57 | $1.01 | ||
| Q3 25 | $0.49 | $0.73 | ||
| Q2 25 | $0.50 | $0.64 | ||
| Q1 25 | $-6.01 | $0.85 | ||
| Q4 24 | $1.04 | $0.81 | ||
| Q3 24 | $0.60 | $0.62 | ||
| Q2 24 | $0.30 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $15.8M |
| Total DebtLower is stronger | $376.1M | $56.6M |
| Stockholders' EquityBook value | $1.2B | $196.3M |
| Total Assets | $2.6B | $377.0M |
| Debt / EquityLower = less leverage | 0.31× | 0.29× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $15.8M | ||
| Q4 25 | $635.6M | $11.3M | ||
| Q3 25 | $646.1M | $9.8M | ||
| Q2 25 | $593.6M | $38.9M | ||
| Q1 25 | $738.4M | $38.1M | ||
| Q4 24 | $428.9M | $44.9M | ||
| Q3 24 | $346.4M | $51.2M | ||
| Q2 24 | $329.2M | $59.5M |
| Q1 26 | — | $56.6M | ||
| Q4 25 | $376.1M | $30.5M | ||
| Q3 25 | $434.5M | $56.3M | ||
| Q2 25 | $430.6M | $28.4M | ||
| Q1 25 | $628.2M | $23.7M | ||
| Q4 24 | $627.0M | $23.6M | ||
| Q3 24 | $625.5M | $20.5M | ||
| Q2 24 | $624.5M | $19.7M |
| Q1 26 | — | $196.3M | ||
| Q4 25 | $1.2B | $195.7M | ||
| Q3 25 | $1.2B | $181.6M | ||
| Q2 25 | $1.1B | $170.5M | ||
| Q1 25 | $1.0B | $161.1M | ||
| Q4 24 | $1.3B | $153.5M | ||
| Q3 24 | $1.3B | $142.2M | ||
| Q2 24 | $1.2B | $133.0M |
| Q1 26 | — | $377.0M | ||
| Q4 25 | $2.6B | $381.1M | ||
| Q3 25 | $2.6B | $409.1M | ||
| Q2 25 | $2.5B | $343.0M | ||
| Q1 25 | $2.6B | $336.4M | ||
| Q4 24 | $2.5B | $352.1M | ||
| Q3 24 | $2.5B | $324.4M | ||
| Q2 24 | $2.5B | $303.9M |
| Q1 26 | — | 0.29× | ||
| Q4 25 | 0.31× | 0.16× | ||
| Q3 25 | 0.38× | 0.31× | ||
| Q2 25 | 0.38× | 0.17× | ||
| Q1 25 | 0.61× | 0.15× | ||
| Q4 24 | 0.47× | 0.15× | ||
| Q3 24 | 0.48× | 0.14× | ||
| Q2 24 | 0.50× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | — |
| Free Cash FlowOCF − Capex | $50.2M | — |
| FCF MarginFCF / Revenue | 13.9% | — |
| Capex IntensityCapex / Revenue | 8.9% | — |
| Cash ConversionOCF / Net Profit | 2.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $82.4M | $28.1M | ||
| Q3 25 | $85.1M | $13.3M | ||
| Q2 25 | $62.9M | $2.0M | ||
| Q1 25 | $24.0M | $2.2M | ||
| Q4 24 | $78.7M | $19.3M | ||
| Q3 24 | $51.0M | $4.9M | ||
| Q2 24 | $43.4M | $16.5M |
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $27.9M | ||
| Q3 25 | $62.2M | $12.8M | ||
| Q2 25 | $47.8M | $1.2M | ||
| Q1 25 | $13.2M | $11.0K | ||
| Q4 24 | $68.3M | $18.0M | ||
| Q3 24 | $32.8M | $4.6M | ||
| Q2 24 | $31.2M | $13.2M |
| Q1 26 | — | — | ||
| Q4 25 | 13.9% | 14.9% | ||
| Q3 25 | 17.4% | 7.0% | ||
| Q2 25 | 13.6% | 0.8% | ||
| Q1 25 | 4.2% | 0.0% | ||
| Q4 24 | 21.2% | 12.5% | ||
| Q3 24 | 10.3% | 3.4% | ||
| Q2 24 | 9.8% | 10.8% |
| Q1 26 | — | — | ||
| Q4 25 | 8.9% | 0.1% | ||
| Q3 25 | 6.4% | 0.3% | ||
| Q2 25 | 4.3% | 0.6% | ||
| Q1 25 | 3.4% | 1.7% | ||
| Q4 24 | 3.2% | 0.9% | ||
| Q3 24 | 5.7% | 0.3% | ||
| Q2 24 | 3.8% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.67× | 2.29× | ||
| Q3 25 | 3.18× | 1.52× | ||
| Q2 25 | 2.32× | 0.26× | ||
| Q1 25 | — | 0.22× | ||
| Q4 24 | 1.41× | 1.96× | ||
| Q3 24 | 1.55× | 0.66× | ||
| Q2 24 | 2.65× | 2.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
LMB
| ODR | $99.8M | 72% |
| GCR | $39.0M | 28% |
